Safety of psychotropic medicines: contribution from observational evidence

Epidemiology and Psychiatric Sciences
Helene Verdoux

Abstract

The risks associated with psychotropic drugs use should be accurately documented at the population level in view of the growing number of persons exposed to these drugs. The strengths of observational studies regarding the identification of drug-related harms mirror the limitations of randomised controlled trials and vice-versa. Observational studies can be carried out in large samples of unselected participants treated in real-life conditions and who may be followed up over long periods. Serious adverse effects undetected during pre-marketing clinical trials may be observed only in post-marketing use, such as metabolic effects of second-generation antipsychotics. Observational studies play a key role in the identification of teratogenic risks, such as those induced by prenatal exposure to anticonvulsants. These studies are the main source of information to investigate the long-term effects of drugs, such as the possible increased risk of dementia in benzodiazepine users. They may also contribute to the accurate assessment at population level of risks overestimated by studies carried out in non-representative samples, such as the risk of congenital heart diseases in babies prenatally exposed to lithium. Owing to the lack of ran...Continue Reading

References

Oct 1, 1977·Acta Psychiatrica Scandinavica·H A AmslerP Vuopio
Jan 12, 1994·JAMA : the Journal of the American Medical Association·L S CohenM L Weiner
Apr 2, 2002·The American Journal of Psychiatry·Michael J SernyakRobert Rosenheck
Apr 5, 2003·Drug News & Perspectives·Jack Botting
Mar 23, 2004·Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists·Melinda J BarkerSimon F Crowe
Mar 1, 2006·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Jan P Vandenbroucke
Apr 4, 2008·International Review of Psychiatry·Jeffrey A Bridge, David A Axelson
Nov 27, 2008·JAMA : the Journal of the American Medical Association·Jan P Vandenbroucke, Bruce M Psaty
Feb 4, 2009·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Corrado BarbuiAndrea Cipriani
Apr 3, 2009·The New England Journal of Medicine·Hans-Georg EichlerTomas Salmonson
Jan 12, 2010·Acta Psychiatrica Scandinavica·H VerdouxB Bégaud
Jun 19, 2010·The New England Journal of Medicine·Janneke JentinkUNKNOWN EUROCAT Antiepileptic Study Working Group
Oct 26, 2011·Pharmacoepidemiology and Drug Safety·Carlos AlvesAna Filipa Macedo
Jan 24, 2012·Lancet·Rebecca F McKnightJohn R Geddes
Oct 10, 2012·BMJ : British Medical Journal·Sophie Billioti de GageAntoine Pariente
Apr 25, 2013·JAMA : the Journal of the American Medical Association·Jakob ChristensenMogens Vestergaard
Apr 1, 2011·Therapeutic Advances in Drug Safety·Yoon K LokeJan P Vandenbroucke
Sep 12, 2014·BMJ : British Medical Journal·Sophie Billioti de GageBernard Bégaud
Jul 28, 2016·American Journal of Public Health·Shilpa N BhupathirajuJoAnn E Manson
Jul 20, 2017·Lancet·Barbara Casassus

❮ Previous
Next ❯

Related Concepts

Related Feeds

Epidemiology of Aging

This feed focuses on epidemiology of aging and aging-related conditions, including Alzheimer’s disease, dementia, and age-associated cognitive impairment. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here